MedTrace Logo

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314

NCT04871646 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 586

Last updated 2021-08-02

No results posted yet for this study

Summary

A Double-blind, Multi-center, Multi-regional, Randomized controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with COVID-19

Conditions

Interventions

DRUG

CKD-314+SOC

CKD-314 is administered intravenously and standard of care is also performed.

DRUG

CKD-314 Placebo+SOC

CKD-314 placebo is administered intravenously and standard of care is also performed..

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Hee Jin Jung, Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-03-31
Completion
2022-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871646 on ClinicalTrials.gov